Roivant Sciences (NASDAQ:ROIV) CEO Sells $6,632,000.00 in Stock

Posted by Geri Gentry on Jun 29th, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. The trade was a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00.
On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $34.07 on Monday. The company’s fifty day moving average is $29.66 and its 200-day moving average is $26.81. The stock has a market cap of $24.51 billion, a price-to-earnings ratio of -56.78 and a beta of 1.13. Roivant Sciences Ltd. has a twelve month low of $10.70 and a twelve month high of $34.68.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last released its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the prior year, the company earned ($0.29) EPS. On average, research analysts anticipate that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently modified their holdings of ROIV. SBI Securities Co. Ltd. raised its position in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences in the fourth quarter valued at approximately $47,000. Finally, Bessemer Group Inc. raised its holdings in shares of Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after purchasing an additional 441 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ROIV has been the topic of a number of research analyst reports. TD Cowen raised their price target on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Sanford C. Bernstein began coverage on Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 target price for the company. HC Wainwright restated a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup raised their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Read Our Latest Stock Report on ROIV

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.